.jpg)
Chardan Capital analyst Keay Nakae maintained a Buy rating on Arrowhead Research (NASDAQ: ARWR) on May 9 and set a price target of $9.50. The company’s shares closed on Friday at $9.88, close to its 52-week high of $9.89.
According to TipRanks.com, Nakae has 0 stars on 0-5 star ranking scale with an average return of -29.4% and a 25.4% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Dicerna Pharma, and Novavax.
Currently, the analyst consensus on Arrowhead Research is Strong Buy and the average price target is $9.13, representing a -7.6% downside.
In a report issued on May 8, Cantor Fitzgerald also upgraded the stock to Buy with a $13 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.89 and a one-year low of $1.42. Currently, Arrowhead Research has an average volume of 1.48M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
